ALEXION - Great Expectations From Label Expansion
We have a positive expectation for the approval of Eculizumab (L, Soliris, Paroxysmal Nocturnal Hemoglobinuria) in Atypical Hemolytic Uremic Syndrome (aHUS, PDUFA on October 7th). Recent data presented in Myasthenia Gravis (MG) shows potential of eculizumab in other indications targeting rare and high unmet need along with robust growth opportunity in approved indication… For more details, please read our report released on September 16, 2011 on Alexion (ALXN), titled “Great Expectations From Label Expansion”.
COMPANIES MENTIONED
ALEXION
ALEXION
More Publications
ALEXION - Geography + Label Expansion = Long Term Growth
US$ 140.00
July 2011
4 pages
ALEXION: Soliris’ Label Expansion & Diversification to Perk ALXN Up!
US$ 140.00
April 2012
5 pages
Niche Products, Label expansion and No Competition - Growth Drivers
US$ 140.00
July 2011
7 pages
Analyzing Automotive Telematics 2016
US$ 750.00
August 2016
130 pages
